GABA consumption

Some gut bacteria make chemical messengers that your nerves also use. Others break those chemicals down. This result estimates your gut community's genetic potential to consume GABA. It offers an exploratory view of microbial function, but its usefulness for predicting disease, choosing treatment, or monitoring recovery hasn't been established.

What the Result Reflects

GABA stands for gamma-aminobutyric acid. It is a chemical messenger that reduces nerve-cell activity in much of the brain and also participates in signaling in the gut. The amount available in either location depends on local production, breakdown, and transport.

Laboratory experiments show that some gut bacteria produce GABA and others use it as a nutrient. Some can do both. GABA-producing strains occur within Bacteroides, Bifidobacterium, and Lactobacillus, but the ability varies between species and strains. A count of one of these bacterial groups doesn't establish how much GABA it produces.

This test uses shotgun sequencing to examine microbial DNA in stool. Computer analysis estimates the community's capacity to consume GABA from the organisms detected and their genetic capabilities. A higher result indicates greater predicted consumption capacity. It doesn't establish how actively those microbes are consuming GABA when you collect the sample.

The result also differs from a chemical measurement of GABA in stool. That concentration reflects what remains after production, consumption, and other processes in the gut. Consumption capacity alone cannot establish whether the final amount is low or high.

Does Higher Consumption Mean Worse Health?

Research hasn't established a consistently beneficial direction for this result. Greater breakdown capacity could influence local GABA availability, but its effect depends on which microbes carry the relevant genes, whether those genes are active, and what else is happening in the gut. There are no validated health targets for this score.

A 2025 international consensus statement on microbiome testing found little evidence so far for using microbiome tests in clinical practice. It also advised against inferring a microbiome's metabolic potential from its list of bacteria alone. Shotgun sequencing reads microbial genes more directly than that, but it still predicts capacity rather than measuring activity.

Human studies have examined several related measurements: bacterial groups, predicted metabolic pathways, stool GABA concentrations, and blood GABA concentrations. These studies help explain why the biology is interesting. Their findings aren't interchangeable with this particular stool consumption result.

Mood and Psychiatric Conditions

A systematic review of 44 observational studies in depression, bipolar disorder, and schizophrenia, covering about 2,500 cases and 2,400 controls, found fairly consistent differences in the overall makeup of gut communities, but not in diversity within each sample. Bacteria linked to glutamate and GABA metabolism were more common across all three conditions. These were mainly GABA producers, such as Lactobacillus, Bifidobacterium, and Enterococcus, and the authors suggested more GABA production rather than more consumption. The shift wasn't specific to any one disorder, and results varied widely between studies. The review did not identify a GABA-consumption pattern that could identify a psychiatric condition.

A separate study compared 127 people with untreated first-episode schizophrenia with 92 healthy controls. It combined stool microbial DNA, chemicals measured in serum, genetic information, and brain imaging, and found associations involving GABA and tryptophan metabolism. Those were broader gut-brain findings, not validation of this consumption score.

These associations don't show that GABA-consuming bacteria cause low mood or schizophrenia. They also don't establish that changing your consumption result will improve symptoms.

Inflammatory Skin Conditions

Bullous pemphigoid is an autoimmune disease that causes large blisters. A study comparing 66 people with the condition with 66 controls who had non-inflammatory skin diseases found greater representation of bacterial pathways related to GABA metabolism. These pathways include steps involved in GABA formation and breakdown. Their enrichment doesn't establish that GABA was depleted in the gut or that this consumption score detects pemphigoid.

In a separate observational study of people with eczema undergoing spa-water treatment, greater predicted microbial GABA degradation was associated with greater improvement in eczema severity. The study lacked a control group, and changes in diet and other circumstances could have influenced the findings. Its pathway analysis was related to this test's biological target, but it did not validate this test's score or show that increasing GABA breakdown caused the improvement.

These findings don't support treating GABA-consuming microbes as uniformly harmful. They concern different diseases, microbial communities, and research measurements.

Alcohol Use

A study of 36 people with alcohol use disorder and a control group found differences in gut bacteria and enrichment of a GABA and glutamate metabolism pathway. The authors tied that pathway to Bacteroides, which they described as a main GABA producer. Thirty of the 36 patients were taking relapse-prevention drugs that act on GABA signaling, and the authors flagged these drugs as a possible influence on the microbiome. The pathway covered broader GABA handling, so the result cannot be read as evidence that this specific consumption score rises with alcohol use.

A secondary analysis of 32 participants in a zonisamide trial examined stool GABA concentrations and microbial functions predicted from 16S sequencing, a different method from the shotgun sequencing behind this result. Higher starting stool GABA was associated with larger reductions in drinking, but the adjusted association did not meet the conventional standard for statistical significance. Zonisamide itself did not change the amount of drinking reduction. This was an exploratory association within a drug trial, and the chemical concentration was a different measurement from consumption capacity. It hasn't established a way to predict your treatment response.

What Studies of Stool GABA Found

The following findings concern GABA measured chemically in stool. They do not establish corresponding increases or decreases in this consumption score.

When Results Can Be Misleading

Studies that sent identical stool samples to multiple commercial microbiome services found substantial differences between services. They assessed broader microbial profiles rather than this particular score, but they show why results from different testing systems cannot be assumed to agree.

• Predicted capacity versus activity: microbial DNA indicates genetic capabilities. It doesn't show whether the relevant genes are active or how quickly GABA is being consumed.
• Relative abundance: the estimated share of microbes with a function can change when other microbes become more or less abundant. That does not necessarily mean their absolute number changed.
• Laboratory and software differences: DNA extraction, sequencing depth, reference genomes, and the rules used to assign functions can affect the result. Similar labels across reports don't make the scores interchangeable.
• Recent biological changes: antibiotics, major dietary changes, and intestinal illness can alter the microbial community. A result collected during these changes may not represent your usual state.
• Collection and storage: contamination, delays, and unsuitable storage conditions can affect the sample. Research protocols and home collection systems use different preservation methods, so a universal rule to freeze stool immediately is inappropriate.
• Gut versus brain: this is a stool microbial measurement. It cannot establish the amount of GABA in your brain or whether your nervous system has too much or too little GABA activity. In germ-free mice, a GABA-producing bacterium raised stool GABA without changing brain GABA.

What a Trend Can Show

Repeated results can describe changes in predicted microbial capacity under comparable testing conditions. A change has no established size or direction that demonstrates better health, and a stable result doesn't rule out disease. Research has not shown that using this score to guide ongoing care improves outcomes.